

CAR-T Funding Report – Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2025



TABLE OF CONTENTS

1. EXECUTIVE SUMMARY	14
1.1 Globally-Approved CAR-T Cell Therapies	15
2. UPTAKE OF CAR-T THERAPIES, FULL YEAR 2017 to 2024	17
2.1 Number of Patients Treated with CAR-T Cell Therapies, Full Year 2017 to 2024	17
2.2 Sales Revenues Generated by FDA-Approved CAR-T Therapies, Full Year 2017-2024	18
2.3 List Prices of U.S. FDA-Approved CAR-T Therapies	19
3. CAR-T FUNDING: AN OVERVIEW	20
3.1 Venture Capital Raised by CAR-T Companies	20
3.1.1 CAR-T Industry Venture Capital Financing Events, January 2014 to February 2025..	21
3.1.2 Venture Capital Funding for CAR-T Companies by Year	24
3.1.3 CAR-T Venture Capital Funding Events from Jan. 2014 to Feb. 2025 (89 Total)	24
3.1.3.1 Bellicum Pharmaceuticals	25
3.1.3.2 CRISPR Therapeutics	25
3.1.3.3 Autolus	25
3.1.3.4 Cellular Biomedicine Group	26
3.1.3.5 Adicet Bio	26
3.1.3.6 Autolus Limited	26
3.1.3.7 Cellular Biomedicine Group	26
3.1.3.9 Carina Biotech	27
3.1.3.10 PeperoMene Bio	27
3.1.3.11 Precision BioSciences	27
3.1.3.12 Cabaletta Bio	28
3.1.3.13 Vor Biopharma	28
3.1.3.14 Gracel Biotechnologies	28
3.1.3.15 Mustang Bio	29
3.1.3.16 Poseida Therapeutics	29
3.1.3.17 BioNTech	29
3.1.3.18 Adicet Bio	30
3.1.3.19 Kyverna Therapeutics	30
3.1.3.20 EXUMA Biotech	30
3.1.3.21 IASO Biotherapeutics	31
3.1.3.22 Legend Biotech	31
3.1.3.23 JW Therapeutics	31
3.1.3.24 Vor Pharma	32
3.1.3.25 ImmPACT Bio	32
3.1.3.26 Synthekine	32
3.1.3.27 Gracell Biotechnologies	32
3.1.3.28 CARsgen Therapeutics	33
3.1.3.29 Umoja Biopharema	33
3.1.3.30 Juventas Cell Therapy	33
3.1.3.31 Celyad Oncology	34
3.1.3.32 Artiva Biotherapeutics	34
3.1.3.33 Caribou Biosciences	34
3.1.3.34 Biosceptre	35
3.1.3.35 Noile-Immune Biotech	35
3.1.3.36 Arcellix	35
3.1.3.37 Cellares Corporation	36
3.1.3.38 Interius BioTherapeutics	36
3.1.3.39 Synthekine	36
3.1.3.40 Umoja Biopharma	37
3.1.3.41 Wugen	37

3.1.3.42	Mnemo Therapeutics	38
3.1.3.43	AvenCell.....	38
3.1.3.44	Currus Biologics	38
3.1.3.45	Juventas Cell Therapy	38
3.1.3.46	Carina Biotech	39
3.1.3.47	IASO Biotherapeutics	39
3.1.3.48	Cellular Biomedicines	39
3.1.3.49	Afflymune Therapeutics	40
3.1.3.50	Leucid Bio	40
3.1.3.51	Clade Therapeutics.....	40
3.1.3.52	SOTIO Biotech	41
3.1.3.53	EXUMA Biotech	41
3.1.3.54	ImmPACT Bio	41
3.1.3.55	Kyverna Therapeutics	42
3.1.3.56	Ucello Therapeutics	42
3.1.3.57	Mustang Bio	42
3.1.3.58	Wugen.....	42
3.1.3.59	Inceptor Bio.....	43
3.1.3.60	Tessa Therapeutics	43
3.1.3.61	Immuneel Therapeutics	43
3.1.3.62	OriCell Therapeutics	43
3.1.3.63	Carina Biotech	43
3.1.3.64	Juventas Cell Therapy	44
3.1.3.65	Arsenal Biosciences.....	44
3.1.3.66	Synthekine	44
3.1.3.67	IASO Biotherapeutics	45
3.1.3.68	MPC Therapeutics	45
3.1.3.69	OriCell Therapeutics	45
3.1.3.70	Verismo Therapeutics	46
3.1.3.71	Cargo Therapeutics	46
3.1.3.72	OneChain Immunotherapeutics	46
3.1.3.73	Caribou Biosciences	47
3.1.3.74	Verismo Therapeutics	47
3.1.3.75	Kyverna Therapeutics	47
3.1.3.76	Gracell Biotechnologies	47
3.1.3.77	Cellares	48
3.1.3.78	Celyad Oncology.....	48
3.1.3.79	Capstan Therapeutics.....	48
3.1.3.80	Limula	49
3.1.3.81	Cargo Therapeutics	49
3.1.3.82	Leman Biotech	49
3.1.3.83	Immuneel Therapeutics	50
3.1.3.84	Dynamic Cell Therapies.....	50
3.1.3.85	Arsenal Biosciences.....	50
3.1.3.86	AvenCell Therapeutics.....	51
3.1.3.87	March Biosciences.....	51
3.1.3.88	A2 Biotherapeutics.....	51
3.1.3.89	Umoja Biopharma	52
4.	IPO FUNDING INVESTED IN CAR-T COMPANIES (42 IPOs).....	53
4.1	Descriptions of IPO Funds Raised by CAR-T Companies, Jan. 2014 to Feb. 2025	55
4.1.1	Juno Therapeutics.....	55
4.1.2	Cellular Biomedicine Group.....	55
4.1.3	Xenetic Biosciences	56
4.1.4	Cellular Biomedicine Group.....	56
4.1.5	Autolus Therapeutics	56

4.1.6	Allogene Therapeutics	57
4.1.7	Precision BioSciences	57
4.1.8	Atara Biotherapeutics.....	57
4.1.9	Xenetic Biosciences	58
4.1.10	Cabaletta Bio.....	58
4.1.11	Atara Biotherapeutics.....	58
4.1.12	Legend Biotech.....	59
4.1.13	Mustang Bio	59
4.1.14	JW Therapeutics.....	59
4.1.15	Atara Biotherapeutics.....	59
4.1.16	Gracell Biotechnologies	60
4.1.17	Vor Biopharma.....	60
4.1.18	Adicet Bio	60
4.1.19	CARsgen Therapeutics	61
4.1.20	Xenetic Biosciences	61
4.1.21	Caribou Biosciences	61
4.1.22	Celyad Oncology	62
4.1.23	Adicet Bio	62
4.1.24	Legend Biotech.....	62
4.1.25	Kyverna Therapeutics	63
4.1.26	Arcellx	63
4.1.27	TC Biopharm.....	63
4.1.28	Celularity	63
4.1.29	TC BioPharm	64
4.1.30	Precision Biosciences	64
4.1.31	Legend Biotech.....	64
4.1.32	TC Biopharm.....	64
4.1.33	Vor Biopharma.....	65
4.1.34	Precigen.....	65
4.1.35	TC Biopharm.....	65
4.1.36	Celularity	65
4.1.37	Legend Biotech.....	66
4.1.38	Coeptis Therapeutics	66
4.1.39	Caribou Biosciences	66
4.1.40	Cargo Therapeutics.....	66
4.1.41	Kyverna Therapeutics	67
4.1.42	Mustang Bio	67
5.	CAR-T LICENSING DEALS (90 Total).....	68
5.1	CAR-T Licensing Deals & Values, January 2015 to February 2025	68
5.1.1	Descriptions of CAR-T Licensing Deals.....	71
5.1.1.1	Collectis & Ohio State University	72
5.1.1.2	bluebird bio & Five Prime Therapeutics	72
5.1.1.3	Poseida Therapeutics & Janssen Biotech	72
5.1.1.4	bluebird bio & ViroMed	73
5.1.1.5	Bellicum Pharmaceuticals & Astellas Pharma	73
5.1.1.6	CRISPR Therapeutics & MaxCyte.....	74
5.1.1.7	bluebird bio & Novartis.....	74
5.1.1.8	Novartis & Celyad	74
5.1.1.9	TC Biopharm & University College London (UCL)	75
5.1.1.10	Mustang Bio & Fred Hutchinson Cancer Research Center	75
5.1.1.11	Mustang Bio & Harvard University.....	75
5.1.1.12	bluebird bio & TC Biopharm.....	76
5.1.1.13	Janssen Biotech & Legend Biotech	76
5.1.1.14	Autolus & UCL Business.....	76
5.1.1.15	Otsuka Pharmaceutical & Osaka University	77

5.1.1.16	Cellular Biomedicine & Novartis	77
5.1.1.17	CRISPR Therapeutics & MaxCyte.....	77
5.1.1.18	Wugen & Washington University	78
5.1.1.19	Atara Biotherapeutics & Memorial Sloan Kettering Cancer Center	78
5.1.1.20	bluebird bio & Inhibrx	78
5.1.1.21	Autolus Therapeutics & Noile-Immune Biotech	79
5.1.1.22	Vor Biopharma & MaxCyte	79
5.1.1.23	Juno Therapeutics & Oxford Biomedica	79
5.1.1.24	Allogene Therapeutics & MaxCyte	80
5.1.1.25	Kite & Teneobio	80
5.1.1.26	Legend Biotech & Noile-Immune Biotech	81
5.1.1.27	Caribou Biosciences & MaxCyte	81
5.1.1.28	Prescient Therapeutics & University of Pennsylvania	81
5.1.1.29	Minerva Biotechnologies & Memorial Sloan Kettering Cancer Center	82
5.1.1.30	Luminary Therapeutics & Case Western Reserve University	82
5.1.1.31	Beam Therapeutics & Oxford Biomedica	82
5.1.1.32	SOTIO Biotech & Unum Therapeutics.....	83
5.1.1.33	Vor Biopharma & Metagenomi.....	83
5.1.1.34	Chimeric Therapeutics & City of Hope.....	83
5.1.1.35	Vor Biopharma & Arbor Biotechnologies	84
5.1.1.36	Immuneel Therapeutics & Hospital Clinic de Barcelona (HCB)	84
5.1.1.37	Vor Biopharma & National Cancer Institute (NCI)	84
5.1.1.38	Caribou Biosciences & Memorial Sloan Kettering Cancer Center	85
5.1.1.39	Carina Biotech & Biomomics	85
5.1.1.40	Atara Biotherapeutics & Bayer.....	85
5.1.1.41	Collectis & SIRION Biotech	86
5.1.1.42	Eli Lilly & Precision BioSciences.....	86
5.1.1.43	AbbVie & Caribou Biosciences	86
5.1.1.44	Luminary Therapeutics & Bio-Techne Corporation	87
5.1.1.45	Wugen & HCW Biologics	87
5.1.1.46	Alpha Biopharma & Wugen	87
5.1.1.47	Servier & Precision Biosciences	88
5.1.1.48	Dr. Reddy's Laboratories & Pregene Biopharma	88
5.1.1.49	Celularity & MaxCyte	88
5.1.1.50	BioNTech & Takara Bio	89
5.1.1.51	Bellicum Pharmaceuticals & UNC Lineberger	89
5.1.1.52	Mustang Bio & Mayo Clinic.....	89
5.1.1.53	Precision Biosciences & Tiziana Sciences	90
5.1.1.54	Arcellx & Oxford Biomedica	90
5.1.1.55	Carina Biotech & BayPAT.....	90
5.1.1.56	Inceptor Bio & University of California	91
5.1.1.57	Rebirthel & Otsuka Pharmaceutical.....	91
5.1.1.58	Kyverna Therapeutics & National Institutes of Health (NIH)	91
5.1.1.59	Intellia Therapeutics & Kyverna Therapeutics	92
5.1.1.60	Antion Biosciences & Allogene Therapeutics	92
5.1.1.61	Sana Biotechnology & IASO Biotherapeutics	92
5.1.1.62	CellPoint & Pregene	93
5.1.1.63	Xenetic Biosciences.....	93
5.1.1.64	GO Therapeutics.....	93
5.1.1.65	LG Chem & MaxCyte.....	94
5.1.1.66	Roche & Poseida Therapeutics	94
5.1.1.67	Chugai Pharmaceutical & Noile-Immune Biotech.....	95
5.1.1.68	Beam Therapeutics & Orbital Therapeutics.....	95
5.1.1.69	Undisclosed Company & Oxford Biomedica.....	96
5.1.1.70	Coeptis Therapeutics & University of Pittsburgh	96
5.1.1.71	Cabaletta Bio & IASO Biotherapeutics	96

5.1.1.72	Inceptor Bio & Avectas	97
5.1.1.73	Kite Pharma & Refuge Biotechnologies	97
5.1.1.74	Kite Pharma & Arcellx	97
5.1.1.75	Cabaletta Bio & Autolus Therapeutics	98
5.1.1.76	Precigen & Alaunos	98
5.1.1.77	Leucid Bio & ImaginAb	99
5.1.1.78	Affini-T Therapeutics & MSK	99
5.1.1.79	Shunxi Holding & Cartherics	99
5.1.1.80	Janssen Biotech & Cellular Biomedicine	100
5.1.1.81	Astellas Pharma & Poseida Therapeutics	100
5.1.1.82	Imugene & Precision Biosciences	100
5.1.1.83	Cabaleta Bio & Oxford Biomedica	101
5.1.1.84	Kyverna Therapeutics & Oxford Biomedica	101
5.1.1.85	Coeptis Therapeutics & Univerdity of Pittsburgh	101
5.1.1.86	Janssen Biotech & Cellular Biomedicine Group	101
5.1.1.87	Legend Biotech & Novartis Pharma	102
5.1.1.88	AbbVie & Umoja Biopharma	102
5.1.1.89	Astellas Pharma & Kelonia Therapeutics	102
5.1.1.90	Allogene Therapeutics & Arbor Biotechnologies	103
6.	CAR-T COLLABORATION DEALS (110 Total)	104
6.1	CAR-T Collaboration Deals between January 2013 and February 2025	104
6.1.1	Descriptions of CAR-T Collaboration Deals Signed from Jan. 2013 to Feb. 2025	108
6.1.1.1	bluebird Bio & Celgene Corporation	108
6.1.1.2	Pfizer, Inc. & Collectis	108
6.1.1.3	Amgen & Kite Pharma	109
6.1.1.4	Five Prime Therapeutics & bluebird bio	109
6.1.1.5	Celgene & Juno Therapeutics	109
6.1.1.6	Collectis & Servier	109
6.1.1.7	Kite Pharma & Cell Design Labs	110
6.1.1.8	Kite Pharma & Fosun Pharma	110
6.1.1.9	Cellular Biomedicine Group & GE Healthcare Life Sciences, China	111
6.1.1.10	Novartis & bluebird bio & Celyad	111
6.1.1.11	Mustang Bio & Harvard University & Beth Israel Deaconess Center	111
6.1.1.12	Jenssen Biotech & Legend Biotech	112
6.1.1.13	PersonGen & Anke Cellular Therapeutics & Miltenyi Biotec	112
6.1.1.14	Kite Pharma & Sangamo Therapeutics	112
6.1.1.15	bluebird bio & Celgene Corporation	113
6.1.1.16	AbbVie & Calibr	113
6.1.1.17	Novartis & Fraunhofer IZI	113
6.1.1.18	Cellular Biomedicine & Novartis	113
6.1.1.19	Regeneron Pharmaceuticals & bluebird bio	114
6.1.1.20	Cartherics & ToolGen	114
6.1.1.21	TC Biopharm & Dublin's Trinity College	114
6.1.1.22	MaxCyte & Kite Pharma	114
6.1.1.23	Phanes Therapeutics & Phanes Biopharmaceuticals & Fosun Kite	115
6.1.1.24	Collectis SA & Servier Monde	115
6.1.1.25	MaxCyte & Allogene Therapeutics	115
6.1.1.26	Fate Therapeutics & Janssen Biotech	116
6.1.1.27	bluebird bio & Bristol Myers Squibb	116
6.1.1.28	Xenetic Biosciences & PJSC Pharmsynthez	116
6.1.1.29	Fate Therapeutics & Baylor College of Medicine	117
6.1.1.30	Beam Therapeutics & Oxford Biomedica	117
6.1.1.31	Carina Biotech & Glytherix	117
6.1.1.32	Chimeric Therapeutics & City of Hope	118
6.1.1.33	Biosceptre & Carina Biotech	118

6.1.1.34	Allogene Tx & University of Texas MD Anderson Cancer Center	118
6.1.1.35	Oxford Biomedica & PhoreMost Limited	119
6.1.1.36	Carina Biotech & Bionomics	119
6.1.1.37	Bayer AG & Atara Biotherapeutics	119
6.1.1.38	Oncternal Therapeutics & Karolinska Institutet	120
6.1.1.39	EXUMA Biotech & Moffitt Cancer Center	120
6.1.1.40	AbbVie & Caribou Biosciences	120
6.1.1.41	Cytovia Therapeutics & Collectis SAS	121
6.1.1.42	JW Therapeutics & Thermo Fisher Scientific	121
6.1.1.43	AbbVie & Caribou Biosciences	121
6.1.1.44	Wugen & Alpha Biopharma	122
6.1.1.45	Dr. Reddy's Laboratories & Shenzhen Pregene Biopharma	122
6.1.1.46	Vor Biopharma & Abound Bio	123
6.1.1.47	Kite Pharma & Fosun Pharmaceutical	123
6.1.1.48	Takara Bio & BioNTech	123
6.1.1.49	Vor Biopharma & Janssen Biotech	124
6.1.1.50	Imugene & Celularity	124
6.1.1.51	Gracell Biotechnologies & FutureGen Biopharm	124
6.1.1.52	AdAlta & Carina Biotech	125
6.1.1.53	Celularity & Oncternal Therapeutics	125
6.1.1.54	Autolus Therapeutics & Blackstone Life Sciences	125
6.1.1.55	4basebio & Leucid Bio	126
6.1.1.56	Leucid Bio & Lonza	126
6.1.1.57	Oxford Biomedica & Arcellx	126
6.1.1.58	Carina Biotech & Bayerische Patentallianz (BayPAT)	127
6.1.1.59	Intellia Therapeutics & Kyverna Therapeutics	127
6.1.1.60	Arsenal Biosciences & Bristol Myers Squibb	127
6.1.1.61	Allogene Therapeutics & Antion Biosciences	128
6.1.1.62	Transgene & PersonGen BioTherapeutics	128
6.1.1.63	Immatix & Bristol Myers Squibb	128
6.1.1.64	Legend Biotech & Janssen Biotech	129
6.1.1.65	Umoja Biopharma & Lupagen	129
6.1.1.66	Immatix & Celgene	129
6.1.1.67	Immatix & Bristol Myers Squibb	130
6.1.1.68	Umoja Biopharma & TreeFrog Therapeutics	130
6.1.1.69	Invectys & University of Texas Cancer Center	131
6.1.1.70	Poseida Therapeutics & Roche	131
6.1.1.71	Chugai Pharmaceutical & Noile-Immune Biotech	131
6.1.1.72	Kite Pharma & Arcellx	132
6.1.1.73	Arsenal Biosciences & Genentech	132
6.1.1.74	Autolus Therapeutics & Bristol Myers Squibb	132
6.1.1.75	Inceptor Bio & Avectos	133
6.1.1.76	JW Therapeutics & 2seventy bio	133
6.1.1.77	Peter MacCallum Cancer Centre and Cartherics	133
6.1.1.78	Umoja Biopharma & IASO Biotherapeutics	134
6.1.1.79	Kite Pharma & Arcellx	134
6.1.1.80	Ori Biotech & Inceptor Bio	134
6.1.1.81	Simnova & Orna Therapeutics	135
6.1.1.82	CARsgen Therapeutics & Huadong Medicine	135
6.1.1.83	TC Biopharm & University of Texas MD Anderson Cancer Center	135
6.1.1.84	Kite Pharma & Arcellx	136
6.1.1.85	Peter MacCallum Cancer Centre & Cartherics	136
6.1.1.86	Cartherics & Shunxi Holding Group	136
6.1.1.87	Autolus Therapeutics & Cardinal Health	137
6.1.1.88	Cartherics & Shunxi	137
6.1.1.89	Janssen Biotech & Cellular Biomedicine	137

6.1.1.90	CytoMed & University of Texas MD Anderson Cancer Center	137
6.1.1.91	Noile-Immune Biotech & Sysmex	138
6.1.1.92	GenScript Biotech & T-MAXIMUM Biotech	138
6.1.1.93	CytoMed Therapeutics & Hangzhou CNK Therapeutics	138
6.1.1.94	CARsgen Therapeutics & Moderna	139
6.1.1.95	Cellares & Bristol Myers Squibb	139
6.1.1.96	Celularity & Regeneron Pharmaceuticals	139
6.1.1.97	Verily & Kyverna Therapeutics	140
6.1.1.98	Kyverna Therapeutics & Elevate Bio	140
6.1.1.99	Kite & Arcellx.....	140
6.1.1.100	Galapagos & Thermo Fisher Scientific	141
6.1.1.101	Calibr-Skaggs & AbbVie.....	141
6.1.1.102	BioNTech & Autolus	141
6.1.1.103	Astellas Pharma & Kelonia Therapeutics.....	142
6.1.1.104	Fiocruz & Caring Cross.....	142
6.1.1.105	Cartherics & TiCARos	142
6.1.1.106	Bristol Myers Squibb	143
6.1.1.107	Chimeric Therapeutics & Cell Therapies	143
6.1.1.108	Nona Biosciences & Umoja Biopharma	143
6.1.1.109	Poseida Therapeutics & Roche	144
6.1.1.110	Takeda & Alloy Therapeutics	144
7.	CAR-T MERGER & ACQUISITION (M&A) DEALS (29 TOTAL)	145
7.1	Descriptions M&A Deals in CAR-T Space, January 2015 to February 205.....	146
7.1.1	Cellular Biomedicine & Chinese PLA General Hospital.....	146
7.1.2	Gilead Sciences & Kite Pharma	146
7.1.3	Gilead Sciences & Cell Design Labs.....	147
7.1.4	Novartis & Endocyte.....	147
7.1.5	Bristol Myers Squibb & Celgene.....	147
7.1.6	Xenetic Biosciences & Scripps Research Institute	147
7.1.7	Astellas Pharma & Xyphos Biosciences.....	148
7.1.8	BioNTech & Neon Therapeutics	148
7.1.9	resTORbio & Adicet Bio.....	149
7.1.10	Century Therapeutics & Empirica Therapeutics	149
7.1.11	Celularity & GX Acquisition.....	149
7.1.12	Cellular Biomedicine & CBMG Merger Sub	150
7.1.13	Amgen & Five Prime Therapeutics	150
7.1.14	BioNTech & Kite	150
7.1.15	ImmPACT Bio & Kalthera.....	150
7.1.16	Kiromic Biopharma & InSilico Solutions.....	151
7.1.17	Allogene Therapeutics & Antion Biosciences	151
7.1.18	FUJIFILM Corporation & Atara Biotherapeutics	151
7.1.19	Galapagos & CellPoint/AboundBio	152
7.1.20	Atossa Therapeutics & Dynamic Cell Therapies	152
7.1.21	Kite & Tmunity Therapeutics	152
7.1.22	Janssen & Cellular Biomedicine	153
7.1.23	Mustang Bio & uBriGene Biosciences	153
7.1.24	Precision Biosciences & Imugene	153
7.1.25	Oxford Biomedica & Institut Merieux.....	154
7.1.26	Clade Therapeutics & Gadeta	154
7.1.27	Kyowa Kirin & Orchard Therapeutics.....	154
7.1.28	AstraZeneca & Gracell Biotechnologies	155
7.1.29	Ginkgo Bioworks & Modulus Therapeutics	155

8.	PROFILES OF COMPANIES INCLUDED IN THIS REPORT	156
8.1	AdAlta Ltd.	156
8.2	Adicet Bio.....	157
8.2.1	Gamma Delta T Cells.....	157
8.3	Afflymune Therapeutics, Inc.	158
8.3.1	Affinity-Tuned CARs.....	158
8.3.2	Real-Time CAR-T Cell Monitoring.....	158
8.4	Allogene Therapeutics	159
8.4.1	AlloCAR-T	159
8.5	Alpha Biopharma.....	160
8.6	Antion Biosciences	160
8.6.1	miCAR-T Technology	160
8.7	Arcellx, Inc.	161
8.7.1	D-Domain Technology.....	161
8.7.2	ddCAR	161
8.7.3	ARC-SparX	161
8.8	Arsenal Biosciences, Inc.	162
8.9	Astellas Pharma, Inc.	163
8.9.1	Partnering.....	163
8.10	Atara Biotherapeutics.....	164
8.11	Autolus Therapeutics PLC	164
8.12	AvenCell Therapeutics, Inc.	165
8.12.1	Universal Switchable CAR Platform.....	165
8.13	Beam Therapeutics	166
8.14	Bellicum Pharmaceuticals, Inc.	167
8.14.1	GoCAR Technology.....	167
8.14.2	CaspaCIDE Technology	167
8.15	Biosceptre.....	168
8.15.1	The Unique Target: nfP2X ₇	168
8.16	BioNTech SE	169
8.16.1	Neoantigen-based T Cell Therapy Platform.....	169
8.17	bluebird bio	170
8.18	Cargo Therapeutics.....	170
8.19	Caribou Biosciences, Inc.	171
8.19.1	Next-Generation CRISPR Technology.....	171
8.19.1	CAR-T Therapy Platform.....	171
8.20	Carina Biotech	172
8.20.1	LGR5 CAR-T Program	172
8.21	CARsgen Therapeutics Holdings Limited	172
8.21.1	CycloCAR.....	173
8.21.2	THANK-uCAR.....	173
8.22	Cartherics Pty Ltd.....	174
8.22.1	Cartherics' CAR-T Cells.....	174
8.23	Cellares.....	174
8.23.1	Cell Shuttle	175
8.24	Collectis	175
8.25	Cellular Biomedicine Group	176
8.26	Celularity, Inc.	176
8.26.1	Power of the Placenta.....	176
8.26.2	NK Cell Platform	177
8.26.3	T Cell Platform	177
8.26.4	Exosome Platform	177
8.27	Celyad Oncology	178
8.27.1	shRNA Platform.....	178
8.27.2	shARC Platform.....	178
8.28	Chengdu Usano Biotechnology Co., ltd. (Ucello).....	179

8.29	Chimeric Therapeutics, Ltd.	179
8.29.1	CLTX CAR-T	179
8.29.2	CDH17 CAR-T	180
8.30	Clade Therapeutics	180
8.30.1	Platform Technologies	180
8.31	Coeptis Therapeutics, Inc.	181
8.31.1	SNAP-CAR	181
8.32	CRISPR Therapeutics	182
8.33	Currus Biologics	182
8.33.1	BEAT Technology	182
8.34	CytoMed Therapeutics Ltd.	183
8.34.1	CAR- $\gamma\delta$ T Cell	183
8.35	Dynamic Cell Therapies, Inc.	183
8.35.1	Platform Technology	184
8.36	Elicera Therapeutics	184
8.37	Galapagos NV	185
8.38	Gracell Biotechnologies	185
8.38.1	FasTCAR	185
8.38.2	TruUCAR	186
8.38.3	SMART CART	186
8.39	EXUMA Biotech Corp.	187
8.39.1	TMR CAR-T Technology	187
8.40	IASO Biotherapeutics	188
8.40.1	Technology Platforms	188
8.41	Immuneel Therapeutics, Pvt., Ltd.	189
8.42	ImmPACT Bio	189
8.42.1	CD19/20 Bispecific CAR	190
8.42.2	TGF- β	190
8.43	Inceptor Bio	191
8.43.1	CAR-M Therapies	191
8.44	Interius BioTherapeutics	191
8.45	Invectys, Inc.	192
8.45.1	IVS-3001: Anti HLA-G CAR-T Cells	192
8.46	Juventas Cell Therapy, Ltd.	193
8.47	JW Therapeutics	193
8.47.1	Carteyva (relma-cel)	193
8.48	Galapagos NV	194
8.48.1	Platform Technology	194
8.49	Kite Pharma (Gilead)	195
8.50	Kyverna Therapeutics	195
8.50.1	“Smarter” CAR-T Cells	196
8.51	Legend Biotech	196
8.51.1	Carvykti	196
8.52	Leucid Bio, Ltd.	197
8.52.1	Lateral CAR Platform	197
8.53	Luminary Therapeutics	198
8.53.1	Gamma 2.0+ Platform	198
8.54	Lupagen, Inc.	198
8.54.1	Side CAR-T Delivery System	199
8.55	MaxCyte, Inc.	199
8.56	Minerva Biotechnologies	200
8.57	Mustang Bio, Inc.	200
8.58	Noile-Immune Biotech	201
8.58.1	PRIME Technology	201
8.59	Novartis AG	202
8.59.1	Approval of Kymriah	202

8.60	OneChain Immunotherapeutics	203
8.61	Oncternal Therapeutics, Inc.....	203
8.61	ROR1	203
8.62	OriCell Therapeutics	204
8.62.1	OriCAR	204
8.63	Oxford Biomedica PLC	205
8.63.1	Lentivector Platform	205
8.63.2	Adeno-Associated Virus Platform.....	205
8.64	Peptomene Bio, Inc.....	206
8.64.1	BAFFR CAR-T Cells	206
8.65	PersonGen Bio Therapeutics (Suzhou) Co., Ltd.....	207
8.66	Poseida Therapeutics, Inc.	208
8.66.1	PiggyBac Platform.....	208
8.66.2	CasCLOVER Platform	208
8.67	Precigen, Inc.....	209
8.67.1	UltraCAR-T Platform	209
8.68	Precision BioSciences.....	210
8.68.1	ARCUS Gene-Editing Platform.....	210
8.69	Prescient Therapeutics	211
8.69.1	OmniCAR	211
8.69.2	CellPryme-M	211
8.69.3	CellPryme-A.....	212
8.70	Simnova Biotherapeutics	212
8.70.1	BiTE CAR-T Platform.....	212
8.71	SOTIO Biotech B.V.	213
8.72	TC BioPharm	213
8.72.1	Gamma Delta T Cells.....	213
8.72.2	T Cell Banks.....	214
8.72.3	Co-Stim CAR-T.....	215
8.73	Umoja Biopharma.....	215
8.73.1	VivoVec In Vivo Gene Delivery	215
8.73.2	RACR-Induced Cytotoxic Lymphocytes (iCIL).....	216
8.73.3	RACR/CAR In Vivo Cell Programming.....	216
8.73.4	TumorTag.....	216
8.74	Verismo Therapeutics, Inc.	217
8.74.1	KIR-CAR Platform	217
8.75	Vor Biopharma	217
8.76	Wugen, Inc.	218
8.77	Xenetic Biosciences, Inc.	218
8.77.1	XBIO-020: DNase I Armored CAR-T	219
8.78	Xyphos Biosciences, Inc.....	219
8.78.1	convertibleCAR Technology.....	219

INDEX OF FIGURES

FIGURE 2.1: Sales Revenues of FDA-Approved CAR-T Therapies, Full Year 2017 to 2024	18
FIGURE 3.1: VC Funding for CAR-T Companies by Year, January 2014 to February 2025	24
FIGURE 4.1: IPO Funding for CAR-T companies, January 2014 to February 2025	54

INDEX OF TABLES

TABLE 1.1: CAR-T Funding Raised through Various Deal Types, Jan. 2014 to Feb. 2025..... 15

TABLE 2.1: Number of Patients Treated with CAR-T Therapies, Full Year 2017-2024 17

TABLE 3.1: Venture Capital Raised by CAR-T Companies, January 2014 to February 2025 21

TABLE 3.1: (CONTINUED) 22

TABLE 3.1: (CONTINUED) 23

TABLE 4.1: IPO Funds raised by CAR-T Companies from January 2014 to February 2025 53

TABLE 4.1: (CONTINUED) 54

TABLE 5.1: CAR-T Licensing Deals Completed from January 2015 to February 2025 68

TABLE 5.1: (CONTINUED) 69

TABLE 5.1: (CONTINUED) 70

TABLE 5.1: (CONTINUED) 71

TABLE 6.1: CAR-T Collaboration Deals Signed from January 2013 to February 2025..... 104

TABLE 6.1: (CONTINUED) 105

TABLE 6.1: (CONTINUED) 106

TABLE 7.1: CAR-T M&A Deals from January 2015 to February 2025 145

TABLE 7.1: (CONTINUED) 146

About BioInformant:

Founded in 2006, BioInformant is the world's first and only market research firm to specialize in the Cell Therapy Industry. Headquartered near Washington, DC, to be situated near the U.S. FDA, NIH, and Capitol Hill, BioInformant has collected 18+ years of historical data on the stem cell industry, providing a robust and unusual foundation on which to base its market research.

To date, BioInformant research has been cited by the *Wall Street Journal* and *Vogue Magazine*, as well as quoted by Tony Robbins in his best-selling book, *LifeForce*.

BioInformant operates the world's largest stem cell industry news site, attracting nearly a million readers per year.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.

